Diffuse Intrinsic Pontine Glioma (DIPG)

Diffuse Intrinsic Pontine Glioma (DIPG) is a childhood brain tumor that arises within the pons — the middle part of the brainstem that controls breathing, heart rate, eye movements, facial expression, swallowing, and the connection between the brain and body. The tumor is 'intrinsic' because it grows from within the brainstem substance itself, and 'diffuse' because it spreads throughout the pons rather than forming a contained mass that could be surgically removed. Because the pons cannot be surgically approached without destroying the vital functions it controls, surgery to remove DIPG is not possible.

DIPG is diagnosed in approximately 300–400 children per year in the US and is the leading cause of brain tumor-related death in children. Median overall survival with standard radiotherapy is approximately 9–11 months from diagnosis. However, clinical trials — particularly ONC201 for H3K27M-mutant DIPG — are producing responses and survival times in individual children that were previously not seen, creating genuine hope that the outcomes for this disease are beginning to change.

The H3K27M mutation is a specific alteration in the genes that encode histone H3 — one of the proteins around which DNA is wrapped in every cell. The mutation changes a single amino acid (lysine to methionine at position 27, giving it the name K27M) on histone H3. This single change has a profound effect: the mutant histone protein inhibits an enzyme (PRC2) that normally adds a repressive chemical mark (H3K27me3) to the genome. Without this mark, genes that should be silenced become active, driving the tumor's growth and identity.

The H3K27M mutation is found in approximately 80% of DIPG cases and is now a defining diagnostic criterion in the 2021 WHO brain tumor classification — tumors with this mutation are formally called 'Diffuse Midline Glioma, H3 K27-altered.' The mutation matters for treatment because it defines a specific molecular target: ONC201, the most promising drug in DIPG, works specifically in H3K27M-mutant tumors. Confirming H3K27M status through biopsy is therefore essential — it is the key to accessing ONC201 trials and other targeted programs.

This is one of the most important misconceptions in DIPG management. For decades, brainstem biopsy in DIPG was considered too dangerous to perform, and children were diagnosed on clinical and imaging grounds alone — without tissue. This meant that molecular diagnosis was not possible, and children could not be enrolled in molecularly-gated clinical trials.

This has changed. Stereotactic biopsy of the pons — performed at specialist pediatric neurosurgery centers using precise frame-based or frameless guidance — is now safe at experienced institutions, with a complication rate below 5%. Most complications are mild and transient (temporary worsening of existing symptoms). Major permanent deficits from pontine biopsy are rare when performed by experienced surgeons at high-volume centers. Tissue diagnosis enables H3K27M confirmation, ACVR1 testing, comprehensive NGS profiling, and enrollment in the most important molecular-eligibility-gated trials. If biopsy has not been offered or the treating center says it cannot be done, the family should ask for referral to a specialist pediatric neurosurgical center that performs pontine biopsies.

The standard treatment for DIPG is focal radiotherapy — delivery of 54 Gy of radiation to the pons over 30 daily treatments (6 weeks). Approximately 70–80% of children experience improvement in neurological symptoms during or after radiotherapy — regaining the ability to walk more steadily, speak more clearly, or control eye movements. This improvement is real and meaningful, though temporary.

Radiotherapy is not curative for DIPG. It reliably produces symptomatic improvement and extends median survival by several months over the natural course of the disease, but essentially all children relapse. Decades of clinical trials adding systemic chemotherapy to radiotherapy have not demonstrated any additional survival benefit beyond radiotherapy alone in randomized studies. This honest reality is why clinical trial enrollment — alongside radiotherapy — is the most important treatment decision a family makes. Every available trial option should be identified at diagnosis, not deferred until after radiotherapy completes or after progression occurs.

ONC201 is an oral small molecule drug that works by activating a mitochondrial enzyme (ClpP) in tumor cells, causing selective death of H3K27M-mutant cells through mitochondrial disruption. It was identified as having activity in DIPG through systematic drug screening against H3K27M-mutant cell lines and was subsequently evaluated in clinical trials and compassionate use programs.

The significance of ONC201 in DIPG is that it has produced responses — including radiologic complete responses, meaning the tumor is no longer visible on MRI — in H3K27M-mutant DIPG patients. Prior to ONC201, no systemic agent had produced reliable responses in DIPG. While complete responses do not occur in all patients and ONC201 is not yet proven to improve overall survival in randomized studies, the responses observed represent an unprecedented development. ONC201 is now being evaluated in multiple international phase 2/3 trials specifically for H3K27M-mutant DMG including DIPG. H3K27M mutation status — confirmed by biopsy — is required for ONC201 trial eligibility. Every H3K27M-mutant DIPG patient should have access to ONC201 through a clinical trial or expanded access program discussed as early as possible after diagnosis.

After completing 6 weeks of radiotherapy, the child typically experiences a period of improvement — the 'honeymoon period' — that lasts approximately 4–6 months on average before the tumor begins to regrow. This post-radiotherapy window is a critical treatment opportunity that should not be allowed to pass without systemic treatment through a clinical trial.

The most important options in the post-radiotherapy maintenance phase include: ONC201 (for H3K27M-mutant tumors — in a trial or expanded access program); ACVR1 inhibitor trials (for ACVR1-mutant tumors); other systemic trial agents targeting PDGFRA, PI3K, HDAC, or other molecular targets; and monitoring with regular MRI. At the time of radiologic and clinical progression — typically 6–9 months from diagnosis — re-irradiation with stereotactic hypofractionated radiotherapy is an established option at specialist centers that produces symptomatic improvement and modest survival prolongation. GD2-directed CAR-T with intracranial delivery is the most active cellular therapy program for relapsed DIPG. Clinical trial enrollment at progression remains the most important treatment avenue.

An ACVR1 mutation in your child's DIPG is an important and actionable finding. ACVR1 (activin receptor type IA) is a receptor that, when mutated, is constitutively active — continuously signaling cells to grow, even without the normal growth signals. This mutation is found in approximately 20–25% of DIPG overall and in approximately 70% of H3.1 K27M-mutant tumors.

The clinical significance is that ACVR1 defines a specific molecular target with dedicated therapeutic programs. Multiple ACVR1 inhibitor drugs — designed to block the constitutively active ACVR1 receptor — are in active clinical trials specifically for ACVR1-mutant DIPG. These trials are eligibility-gated on biopsy-confirmed ACVR1 mutation and are not accessible without tissue confirmation of the mutation. If your child's biopsy has confirmed an ACVR1 mutation, identifying and enrolling in an ACVR1 inhibitor trial is a priority. A specialist DIPG second opinion can identify which ACVR1 inhibitor trials are currently open and accepting patients, and CancerFax can support international coordination where needed.

Yes — and for families who have exhausted or cannot access available options through local or Western trial networks, international trial access is an important consideration. China has active DIPG clinical programs at specialist pediatric oncology centers — including GD2-directed CAR-T cell therapy with intracranial delivery, novel combination immunotherapy approaches, and access to agents in development that may not be available through Western trial routes. Several Chinese institutions have dedicated pediatric neuro-oncology programs with growing DIPG research infrastructure.

In the US, Canada, UK, Europe, and Australia, the major cooperative groups — Pediatric Brain Tumor Consortium (PBTC), Children's Oncology Group (COG), ITCC, SIOPE — run the majority of active DIPG trials. ONC201 trials are running across multiple international sites. ACVR1 inhibitor programs are increasingly multi-national. Matching a child's molecular profile (H3K27M status, ACVR1 mutation, full NGS) against currently open trials globally requires specialized knowledge of the trial landscape. CancerFax specifically supports families in this matching process and in coordinating access to international trial sites, including in China, where families may find programs not accessible through their home country's trial network.

Yes — and we understand that for DIPG families, time is the most critical resource. CancerFax supports DIPG families by reviewing MRI reports, biopsy pathology, H3K27M mutation results, ACVR1 testing, comprehensive NGS profiling, and treatment records to confirm the molecular diagnosis and identify every available clinical trial option for which the child may be eligible.

We prioritize: identifying ONC201 trial access for every H3K27M-mutant patient; locating ACVR1 inhibitor trials for ACVR1-mutant patients; identifying GD2-CAR-T programs at centers globally including in China; coordinating specialist DIPG second opinion consultations with pediatric neuro-oncologists at institutions with active research programs; and supporting families in navigating the practical steps of international trial access — including report translation, center liaison, and travel and logistics coordination. We know that DIPG families are navigating the unimaginable, and our commitment is to ensure that no family misses an available option because of information, access, or coordination barriers. Please send your child's medical reports and we will respond as quickly as possible.